Functional assays supported this mechanistic link: suppression of the IL-6-STAT3 pathway improved docetaxel sensitivity in prostate cancer cell lines, and in vivo experiments confirmed significantly reduced tumor volume and weight in mice treated with docetaxel, an effect that was diminished in dysbiotic mice. Here, IL6 is linked to prostate carcinoma.